Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab


  • Jeffrey S. Ross
  • Jonathan A. Fletcher
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_2677-3



The proto-oncogene HER-2/neu (ERBB2) is located on chromosome band 17q21.1 and encodes a transmembrane receptor tyrosine kinase. The name for the HER-2 protein is derived from “human epidermal growth factor receptor” as it features substantial homology with the epidermal growth factor receptor (EGFR).


The HER-2/neu (p185neu) protein belongs to a family of closely related growth factor receptors including.
  • HER-1 (ERBB1), EGFR

  • HER-2 (ERBB2)

  • HER-3 (ERBB3)

  • HER-4 (ERBB4)

HER-2/neu gene amplificationand protein overexpression have been identified in 10–34 % of breast cancers, and patients whose breast cancers contain HER-2/neu aberrations have a poor prognosis. The prognostic impact of HER-2/neu amplification was initially most convincing in patients with axillary lymph node metastases. By contrast, a prognostic role was less compelling in patients with localized...


Breast Cancer Epidermal Growth Factor Receptor Human Epidermal Growth Factor Receptor Target Cancer Stem Cell Antigen Retrieval Technique 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Press MF, Bernstein L, Thomas PA et al (1997) Her-2/neu gene amplification characterized by fluorescence in situ hybridization; poor prognosis in node-negative breast carcinomas. J Clin Oncol 15:2894–2904PubMedGoogle Scholar
  2. Romond EH, Perez EA, Bryant J, Suman VJ et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684CrossRefPubMedGoogle Scholar
  3. Ross JS, Fletcher JA, Linette GP et al (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8:307–325CrossRefPubMedGoogle Scholar
  4. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182CrossRefPubMedGoogle Scholar
  5. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Albany Medical CollegeAlbanyUSA